tiprankstipranks
Compass Therapeutics, Inc. (CMPX)
NASDAQ:CMPX
US Market
CMPX
Compass Therapeutics
RESEARCH TOOLSreports
Want to see CMPX full AI Analyst Report?

Compass Therapeutics (CMPX) Stock Forecast & Price Target

564 Followers
See the Price Targets and Ratings of:

CMPX Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Compass
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CMPX Stock 12 Month Forecast

Average Price Target

$9.33
▲(350.89% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Compass Therapeutics in the last 3 months. The average price target is $9.33 with a high forecast of $24.00 and a low forecast of $6.00. The average price target represents a 350.89% change from the last price of $2.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.333333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,3.609230769230769,5.308461538461539,7.007692307692308,8.706923076923077,10.406153846153847,12.105384615384615,13.804615384615385,15.503846153846155,17.203076923076924,18.902307692307694,20.601538461538464,22.30076923076923,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.481025641025641,3.052051282051282,3.6230769230769226,4.194102564102564,4.765128205128205,5.336153846153846,5.907179487179487,6.478205128205128,7.049230769230769,7.6202564102564105,8.191282051282052,8.762307692307692,{"y":9.333333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.2246153846153844,2.539230769230769,2.853846153846154,3.168461538461538,3.483076923076923,3.7976923076923077,4.112307692307692,4.426923076923077,4.741538461538462,5.056153846153847,5.3707692307692305,5.685384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.43,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$24.00Average Price Target$9.33Lowest Price Target$6.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on CMPX
Andrew Berens
Leerink Partners
Leerink Partners
$4→$7
Buy
238.16%
Upside
Reiterated
08/07/26
Compass Therapeutics price target raised to $7 from $4 at LeerinkCompass Therapeutics price target raised to $7 from $4 at Leerink
Piper Sandler Analyst forecast on CMPX
Biren Amin
Piper Sandler
Piper Sandler
$4→$6
Buy
189.86%
Upside
Reiterated
08/07/26
Piper Sandler Keeps Their Buy Rating on Compass Therapeutics (CMPX)
William Blair Analyst forecast on CMPX
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on CMPX
John Newman
Canaccord Genuity
Canaccord Genuity
$7
Buy
238.16%
Upside
Reiterated
08/07/26
Compass Therapeutics (CMPX) Gets a Buy from Canaccord Genuity
H.C. Wainwright Analyst forecast on CMPX
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$24
Buy
1059.42%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)
LifeSci Capital Analyst forecast on CMPX
Charles Zhu
LifeSci Capital
LifeSci Capital
$6
Buy
189.86%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX) and Halozyme (NASDAQ: HALO)
Stifel Nicolaus Analyst forecast on CMPX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$6
Buy
189.86%
Upside
Reiterated
06/01/26
Stifel Nicolaus Sticks to Their Buy Rating for Compass Therapeutics (CMPX)
Guggenheim Analyst forecast on CMPX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$12→$8
Buy
286.47%
Upside
Reiterated
05/06/26
Guggenheim Remains a Buy on Compass Therapeutics (CMPX)
Craig-Hallum Analyst forecast on CMPX
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Raymond James Analyst forecast on CMPX
Sean McCutcheon
Raymond James
Raymond James
―
Hold
―
Downgraded
04/28/26
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond JamesCompass Therapeutics downgraded to Market Perform from Outperform at Raymond James
Jefferies Analyst forecast on CMPX
Maury Raycroft
Jefferies
Jefferies
$9
Buy
334.78%
Upside
Reiterated
04/27/26
Compass Therapeutics selloff 'an over-reaction,' says JefferiesCompass Therapeutics selloff 'an over-reaction,' says Jefferies
Wedbush Analyst forecast on CMPX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$8
Buy
286.47%
Upside
Reiterated
03/06/26
Wedbush Keeps Their Buy Rating on Compass Therapeutics (CMPX)
Cantor Fitzgerald Analyst forecast on CMPX
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/03/25
Compass Therapeutics initiated with an Overweight at Cantor FitzgeraldCompass Therapeutics initiated with an Overweight at Cantor Fitzgerald
Citizens JMP Analyst forecast on CMPX
Reni Benjamin
Citizens JMP
Citizens JMP
$10
Buy
383.09%
Upside
Initiated
12/03/25
Compass Therapeutics initiated with an Outperform at Citizens JMPCompass Therapeutics initiated with an Outperform at Citizens JMP
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on CMPX
Andrew Berens
Leerink Partners
Leerink Partners
$4→$7
Buy
238.16%
Upside
Reiterated
08/07/26
Compass Therapeutics price target raised to $7 from $4 at LeerinkCompass Therapeutics price target raised to $7 from $4 at Leerink
Piper Sandler Analyst forecast on CMPX
Biren Amin
Piper Sandler
Piper Sandler
$4→$6
Buy
189.86%
Upside
Reiterated
08/07/26
Piper Sandler Keeps Their Buy Rating on Compass Therapeutics (CMPX)
William Blair Analyst forecast on CMPX
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Canaccord Genuity Analyst forecast on CMPX
John Newman
Canaccord Genuity
Canaccord Genuity
$7
Buy
238.16%
Upside
Reiterated
08/07/26
Compass Therapeutics (CMPX) Gets a Buy from Canaccord Genuity
H.C. Wainwright Analyst forecast on CMPX
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$24
Buy
1059.42%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)
LifeSci Capital Analyst forecast on CMPX
Charles Zhu
LifeSci Capital
LifeSci Capital
$6
Buy
189.86%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX) and Halozyme (NASDAQ: HALO)
Stifel Nicolaus Analyst forecast on CMPX
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$6
Buy
189.86%
Upside
Reiterated
06/01/26
Stifel Nicolaus Sticks to Their Buy Rating for Compass Therapeutics (CMPX)
Guggenheim Analyst forecast on CMPX
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$12→$8
Buy
286.47%
Upside
Reiterated
05/06/26
Guggenheim Remains a Buy on Compass Therapeutics (CMPX)
Craig-Hallum Analyst forecast on CMPX
Albert Lowe
Craig-Hallum
Craig-Hallum
―
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Raymond James Analyst forecast on CMPX
Sean McCutcheon
Raymond James
Raymond James
―
Hold
―
Downgraded
04/28/26
Compass Therapeutics downgraded to Market Perform from Outperform at Raymond JamesCompass Therapeutics downgraded to Market Perform from Outperform at Raymond James
Jefferies Analyst forecast on CMPX
Maury Raycroft
Jefferies
Jefferies
$9
Buy
334.78%
Upside
Reiterated
04/27/26
Compass Therapeutics selloff 'an over-reaction,' says JefferiesCompass Therapeutics selloff 'an over-reaction,' says Jefferies
Wedbush Analyst forecast on CMPX
Unknown Analyst
Wedbush
Not Ranked
Wedbush
$8
Buy
286.47%
Upside
Reiterated
03/06/26
Wedbush Keeps Their Buy Rating on Compass Therapeutics (CMPX)
Cantor Fitzgerald Analyst forecast on CMPX
Li Watsek
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
12/03/25
Compass Therapeutics initiated with an Overweight at Cantor FitzgeraldCompass Therapeutics initiated with an Overweight at Cantor Fitzgerald
Citizens JMP Analyst forecast on CMPX
Reni Benjamin
Citizens JMP
Citizens JMP
$10
Buy
383.09%
Upside
Initiated
12/03/25
Compass Therapeutics initiated with an Outperform at Citizens JMPCompass Therapeutics initiated with an Outperform at Citizens JMP
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Compass Therapeutics

3 Months
Charles ZhuLifeSci Capital
Success Rate
5/8 ratings generated profit
63%
Average Return
+8.46%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +8.46% per trade.
1 Year
Stephen WilleyStifel Nicolaus
Success Rate
8/13 ratings generated profit
62%
Average Return
+48.92%
Copying Stephen Willey's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +48.92% per trade.
2 Years
Stephen WilleyStifel Nicolaus
Success Rate
6/13 ratings generated profit
46%
Average Return
-4.92%
Copying Stephen Willey's trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of -4.92% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CMPX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
24
18
12
9
Buy
9
10
6
2
1
Hold
1
1
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
35
25
14
10
In the current month, CMPX has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CMPX average Analyst price target in the past 3 months is 9.33.
Each month's total comprises the sum of three months' worth of ratings.

CMPX Financial Forecast

CMPX Earnings Forecast

Next quarter’s earnings estimate for CMPX is -$0.12 with a range of -$0.15 to -$0.09. The previous quarter’s EPS was -$0.13. CMPX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year CMPX has Performed in-line its overall industry.
Next quarter’s earnings estimate for CMPX is -$0.12 with a range of -$0.15 to -$0.09. The previous quarter’s EPS was -$0.13. CMPX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year CMPX has Performed in-line its overall industry.

CMPX Sales Forecast

Next quarter’s sales forecast for CMPX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year CMPX has Performed in-line its overall industry.
Next quarter’s sales forecast for CMPX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CMPX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year CMPX has Performed in-line its overall industry.

CMPX Stock Forecast FAQ

What is CMPX’s average 12-month price target, according to analysts?
Based on analyst ratings, Compass Therapeutics, Inc.’s 12-month average price target is 9.33.
    What is CMPX’s upside potential, based on the analysts’ average price target?
    Compass Therapeutics, Inc. has 350.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CMPX a Buy, Sell or Hold?
          Compass Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Compass Therapeutics, Inc.’s price target?
            The average price target for Compass Therapeutics, Inc. is 9.33. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $24.00 ,the lowest forecast is $6.00. The average price target represents 350.89% Increase from the current price of $2.07.
              What do analysts say about Compass Therapeutics, Inc.?
              Compass Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of CMPX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.